Nabriva Therapeutics Announces Pricing of $15 Million Public Offering by Seini Moimoi | Dec 10, 2020 | Portfolio News
Tricida Announces Updates on Veverimer Development Program, Regulatory Status and New Patent Extending Protection through 2038 by Seini Moimoi | Dec 8, 2020 | Portfolio News
Neurana Pharmaceuticals Announces Top-Line Results from Tolperisone Phase 1 CNS Effects Study by Seini Moimoi | Dec 8, 2020 | Portfolio News
Nabriva Therapeutics and Sinovant Sciences Restructure License Agreement for XENLETA for Community-Acquired Bacterial Pneumonia in China by Seini Moimoi | Dec 7, 2020 | Uncategorized
Nabriva Therapeutics and Sinovant Sciences Restructure License Agreement for XENLETA for Community-Acquired Bacterial Pneumonia in China by Seini Moimoi | Dec 7, 2020 | Portfolio News
